NextFin News - Novartis has agreed to buy Myricx Bio for up to $1.5 billion, a deal that gives the Swiss drugmaker access to a pre-clinical cancer-drug platform built around a novel antibody-drug conjugate payload. Novartis said it will pay $1.1 billion upfront and as much as $400 million in milestone payments, with closing expected in the second half of 2026, subject to regulatory approvals and other customary conditions.
The transaction is a clear signal that Novartis wants more than incremental oncology exposure. It is paying for a payload technology that it says could broaden the use of antibody-drug conjugates across solid tumors, not for an approved product that can contribute revenue immediately. Myricx is a privately held UK biotechnology company that said it was founded in 2019 and developed its program as a spinout from Imperial College London and the Francis Crick Institute.
Novartis said Myricx is developing two lead ADC assets directed toward B7-H3 and HER2, with a broader N-myristoyltransferase inhibitor, or NMTi, payload platform designed to address resistance to current payloads. That matters because the current ADC market is increasingly shaped by chemistry, not just target selection. If a new payload class can improve tolerability or overcome resistance, it can become the foundation for multiple future programs.
For Novartis, the deal also fits a familiar corporate pattern. The company has spent years trying to build around oncology platforms that can be reused across indications and drug families, and it said this acquisition reflects that approach. The strategic logic is simple: when scientific differentiation is hard to find internally, buy it before a rival does.
Why Novartis Is Paying For A Platform
The most important point is that Novartis is buying optionality. Myricx does not yet have a commercial drug. It has preclinical data, a mechanism of action and a set of targets that look commercially relevant, but the true value of the transaction depends on whether the payload translates into human benefit.
Novartis said the NMTi payload is designed to deliver a differentiated cancer-killing payload directly to tumor cells and may address limitations of commonly used ADC payload classes such as TOPO-1 inhibitors. The company also said preclinical data suggest activity across solid tumors, including TOPO-1-resistant models. Those are encouraging claims, but they remain claims about the laboratory stage, not about patient outcomes.
“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, president of biomedical research at Novartis.
That is the strategic heart of the deal. Novartis is not saying the ADC category has peaked. It is saying the category is still evolving and that payload differentiation may be the next competitive frontier. In a crowded field, a new payload mechanism can be more valuable than another antibody aimed at an already familiar target.
Myricx’s own history adds context to why this acquisition is notable. The company said it raised £90 million in a Series A in 2024 led by Novo Holdings and Abingworth, with participation from British Business Bank, Cancer Research Horizons and Eli Lilly, among others. That financing suggests the scientific case had already attracted serious backing before the buyout. It also explains why a large pharmaceutical company would be willing to pay up now rather than wait for more mature data.
“There is a widely recognised and critical unmet need for new ADC payloads that can improve the standard of care over current payloads, overcome payload resistance, improve tolerability and offer a wider therapeutic index,” said Mohit Rawat, chief executive of Myricx Bio.
That statement is not just deal rhetoric. It describes the precise gap Myricx is trying to fill. The problem with many ADCs is not simply whether they hit the target. It is whether the payload can be delivered safely enough, and selectively enough, to maximize efficacy without forcing dose reductions or treatment interruptions. A payload that improves that balance would have genuine strategic value.
What The Deal Says About Oncology Competition
The acquisition fits a broader reality in oncology: large drugmakers are increasingly buying the science that they think can still matter a decade from now. In practice, that means platform assets with the possibility of repeat use, rather than one-off programs that can be hard to scale beyond a single readout.
ADC development is a particularly attractive area for that kind of bet because it combines established clinical demand with a still-open innovation path. If current payload classes run into resistance or tolerability ceilings, there is room for a company that can offer a differentiated mechanism. That is what makes Myricx interesting to Novartis and potentially interesting to competitors watching the space.
Novartis said the acquisition would strengthen its oncology pipeline with two lead ADC assets and a broader payload platform, and the company explicitly linked the deal to its broader strategy of scaling innovative platforms. The comparison it made to radioligand therapy is important: it suggests that Novartis sees a pathway from early modality investment to long-term commercial franchise building.
The deal size also reflects the market’s willingness to reward differentiated oncology science even before clinical proof arrives. A headline value of up to $1.5 billion is large for a preclinical asset, but the structure matters. The company is paying $1.1 billion upfront and tying another $400 million to milestones, which keeps part of the price contingent on future progress rather than upfront faith alone.
That structure tells you something else as well: Novartis is comfortable taking a measured risk on a platform if it thinks the science could create multiple shots on goal. In other words, it is buying a library, not a single chapter.
Why The Structure Matters More Than The Headline Price
It is easy to focus on the $1.5 billion headline value and assume the deal is mostly about size. It is not. The real story is that the economics are staged around a scientific experiment still in progress.
The $1.1 billion upfront payment gives Novartis immediate access to the platform, while the remaining $400 million in milestone payments preserves downside protection if the program fails to progress. That is a common feature of pharma dealmaking, but it is especially important here because the acquired assets are preclinical.
Myricx says its platform is based on N-myristoyltransferase inhibition, or NMT inhibition, a mechanism it believes may offer a differentiated payload profile compared with existing ADC chemistry. Novartis said the company’s lead assets are directed to B7-H3 and HER2, two targets that have become increasingly important in solid-tumor development because they can support a range of therapeutic strategies.
The critical question is whether that chemistry can hold up in the clinic. Preclinical activity is useful, but it does not guarantee tolerability, durability or a clean regulatory path. That is why the milestone-heavy structure matters: it prices in the possibility that the science may not scale beyond the lab.
What Happens Next
The next milestone is the closing process. Novartis said it expects the transaction to close in the second half of 2026, subject to regulatory approvals and other customary closing conditions. After that, the market will be watching for any updates on development plans, platform validation and whether the acquired science can be advanced into clinical testing at the pace Novartis wants.
For investors and industry rivals, the broader implication is that oncology M&A is still being driven by the search for differentiated platforms rather than just late-stage assets. Novartis is effectively betting that the next meaningful step in ADC innovation will come from payload chemistry that can overcome resistance and widen the therapeutic window.
That is a rational bet, but it is still a bet. If Myricx’s payload works in patients, the acquisition could look prescient. If it does not, the value will remain confined to a scientific thesis that never became a drug.
Novartis is buying the right kind of uncertainty: one with enough promise to justify a premium, but enough risk to keep part of the price conditional. In oncology, that is often the only way to buy tomorrow’s platform without paying for tomorrow’s certainty.
Explore more exclusive insights at nextfin.ai.
